J&J scut­tles PhI­II lu­pus pro­gram on failed da­ta analy­sis; No­var­tis pays $345M to re­solve bribery charges

→ J&J’s high hopes for broad­en­ing the use of Ste­lara to cov­er sys­temic lu­pus ery­the­mato­sus has foundered in Phase III. Re­searchers called it quits af­ter the drug failed a pre-planned in­ter­im ef­fi­ca­cy analy­sis. J&J al­so said that it will scrap plans for a sep­a­rate Phase III tri­al in Chi­na.

→ Nas­daq con­tin­ues to host the hottest game on the street as the lat­est string of biotech IPOs roll out.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER